| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Bradykinin is a tissue-based system that has strong effects on the heart and kidneys. A highly sensitive amino-terminal directed radioimmunoassay that detects bradykinin-(1-7), bradykinin-(1-8) using high-performance liquid chromatography, and bradykinin-(1-9) was created in order to examine the regulation of this system. Bradykinin was identified using carboxyl-terminal guided radioimmunoassay in rat kidney and blood. Bradykinin-(1-9) (~100 fmol/g tissue wet weight) and Bradykinin-(1-7) (~70 fmol/g) are the two main bradykinin peptides found in the kidney. Of these, Bradykinin-(1-8) is detectable (~8 fmol/g) and Bradykinin-(4-9) (~12 fmol/g); Bradykinin-(2-9) and Bradykinin-(3-9) are below the detection limit. Bradykinin-(1–9) is only found in blood at extremely low concentrations (~2 fmol/ml), and the detection limit for other bradykinin peptides is exceeded. The angiotensin-converting enzyme (ACE) inhibitor perindopril administered with renal levels of bradykinin-1–8, bradykinin–9, and bradykinin–(1–7) roughly triples as well as reduces correlation. Bradykinin:(1–9) proportion. The aorta, adrenal glands, brain, adrenal glands, heart, and brown adipose tissue can all be treated with N-terminal guided radioimmunoassay. Bradykinin-(1-7) and bradykinin-(1-9) abundances for these tissues are comparable (16-340 fmol/g), although levels of bradykinin-(1-8) are lower[1].
|
|---|---|
| References |
| Molecular Formula |
C44H61N11O10
|
|---|---|
| Molecular Weight |
904.02300
|
| Exact Mass |
903.46
|
| CAS # |
16875-11-9
|
| PubChem CID |
14694060
|
| Appearance |
White to off-white solid powder
|
| Density |
1.47g/cm3
|
| Index of Refraction |
1.684
|
| LogP |
0.951
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
65
|
| Complexity |
1700
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
|
| InChi Key |
ZZHVXIPXTCBVBE-POFDKVPJSA-N
|
| InChi Code |
InChI=1S/C44H61N11O10/c45-44(46)48-20-8-16-30(43(64)65)51-38(59)32(24-28-13-5-2-6-14-28)52-40(61)35-18-10-22-55(35)42(63)33(26-56)53-37(58)31(23-27-11-3-1-4-12-27)50-36(57)25-49-39(60)34-17-9-21-54(34)41(62)29-15-7-19-47-29/h1-6,11-14,29-35,47,56H,7-10,15-26H2,(H,49,60)(H,50,57)(H,51,59)(H,52,61)(H,53,58)(H,64,65)(H4,45,46,48)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
|
| Chemical Name |
(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-1-[(2S)-3-hydroxy-2-[[(2S)-3-phenyl-2-[[2-[[(2S)-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~110.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1062 mL | 5.5309 mL | 11.0617 mL | |
| 5 mM | 0.2212 mL | 1.1062 mL | 2.2123 mL | |
| 10 mM | 0.1106 mL | 0.5531 mL | 1.1062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
